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236 Abstract 
37
38 This narrative review aims to critically evaluate scientific evidence exploring the therapeutic role(s) 
39 of long-chain omega-3 polyunsaturated fatty acids (Ω-3PUFA) in the context of ageing, and 
40 specifically, sarcopenia. We highlight that beyond impairments in physical function and a lack of 
41 independence, the age-related decline in muscle mass has ramifications for cardio-metabolic health. 
42 Specifically, skeletal muscle is crucial in regulating blood glucose homeostasis (and by extension 
44 critical for survival during muscle wasting conditions (i.e. AIDS). Recent interest in the potential 
45 anabolic action of Ω-3PUFA is based on findings from experimental studies that measured acute 
46 changes in the stimulation of muscle protein synthesis (MPS) and/or chronic changes in muscle mass 
47 and strength in response to fish oil-derived Ω-3PUFA supplementation. Key findings include a 
48 potentiated response of MPS to amino acid provision or resistance-based exercise with Ω-3PUFA in 
49 healthy older adults that extrapolated to longer-term changes in muscle mass and strength. The key 
50 mechanism(s) underpinning this enhanced response of MPS remains to be fully elucidated, but is 
51 likely driven by the incorporation of exogenous Ω-3PUFA into the muscle phospholipid membrane 
52 and subsequent upregulation of cell signaling protein known to control MPS. In conclusion, multiple 
53 lines of evidence suggest that dietary Ω-3PUFA provide an essential link between musculoskeletal 
54 and cardio-metabolic health in older adults. Given that western diets are typically meagre in Ω-
55 3PUFA content, nutritional recommendations for maintaining muscle health with advancing age 
56 should place greater emphasis on dietary Ω-3PUFA intake.   
57
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43 reducing type diabetes 2 (T2DM) risk) and providing gluconeogenic precursors that are mellitus 
369 Introduction
70 The amount and type of dietary fat consumed is widely recognised to play an important role in 
71 determining metabolic health in humans (1). Fatty acids are hydrocarbon chains of varying lengths 
72 with a carboxyl group and methyl group at opposing ends. The presence of one or several double 
73 bonds in (unsaturated) fatty acids impact on their conformation, as well as their function. Very long-
74 chain or long-chain omega-3 polyunsaturated fatty acids, abbreviated Ω-3PUFA throughout this 
75 review, are a class of fatty acids distinguished by two or more double bonds at the methyl end of the 
76 carbon chain. The most abundant species of Ω-3PUFA are eicosapentaenoic acid (EPA), 
77 docosahexaenoic acid (DHA) and alpha-linolenic acid (ALA). EPA consists of a 20-carbon chain 
78 with 5 double bonds, DHA a 22-carbon chain with 6 double bonds, and ALA an 18-carbon chain with 
79 3 double bonds. As humans are unable to endogenously synthesise ALA, it is defined as an essential 
80 fatty acid that must be acquired from the diet. The most commonly cited health benefit associated 
81 with increasing dietary Ω-3PUFA intake relates to a reduction in cardiovascular disease (CVD) risk 
82 (2), as mediated by improvements in the regulation of blood pressure, vascular function and cardiac 
83 rhythm, although recent evidence has cast doubt on some of these claims. Recent evidence also 
84 proposes a physiological role for Ω-3PUFA in regulating skeletal muscle protein metabolism (3) and, 
85 by extension, muscle mass (4), muscle strength (5) and muscle function. Other papers in this volume 
86 focus on the impact of dietary fatty acids on liver fat content and metabolism (6) and regional/ectopic 
87
88 skeletal muscle tissue and, specifically, the role of Ω-3PUFA in the context of sarcopenia and 
89 sarcopenic obesity. Our narrative is divided into three distinct themes. First, we identify food sources 
90
91 the importance of skeletal muscle tissue for cardio-metabolic health, physical function and disease 
92 prevention in humans. Finally, we critique available evidence that evaluates the role of Ω-3PUFA as 
93 a component of non-pharmacological strategies designed to tackle sarcopenia and sarcopenic obesity. 
94
95 Dietary Sources of Long Chain Omega-3 Polyunsaturated Fatty Acids
96 Commonly consumed food sources rich in Ω-3PUFA include oily fish such as mackerel, sardines, 
97 trout and salmon (Figure 1). In comparison, canned tuna contains a lower Ω-3PUFA content and is 
98 no longer categorised as an oil-rich fish. While other non-fish food sources such as walnuts also 
99 contain Ω-3PUFA, the Ω-3PUFA are shorter chain (often ALA) which, in humans, are poorly 
100 converted to EPA and then DHA through processes of elongation and desaturation. Interestingly, this 
101 conversion is poorer in men than women (7).  
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of Ω-3PUFA and their consumption at the population level. Next, we provide a holistic overview of 
fat depots in human adipose tissue [please insert Petrus 19 PNS here]. This review focuses on human 
4102 <<< Insert Figure 1 here >>>
103 Dietary guidelines in the UK recommend two, 140g, portions of fish per week, one of which should 
104 be of oily source (8). However, the latest National Diet and Nutrition Survey (9) indicates that, on 
105 average, adults aged 19-64 years consume only 56g of oily fish on a weekly basis (excluding canned 
106 tuna), while older adults aged 65+ consume 84g of oily fish per week. While the average oily fish 
107 intake falls alarmingly short of this 140g recommendation, also noteworthy is the median intake for 
108 both age groups is 0g per week, with the majority of UK adults avoiding dietary intake of oily fish 
109 altogether. Evidence from the EPIC-Norfolk study highlights that cod liver oil (a source of Ω-3PUFA) 
110 was the most popular supplement (consumed by 32% of men and 45% of women) (10). However, it is 
111 worth noting that over-the-counter fish oil preparations do not always contain the dose advertised on 
112 the label, and that the fatty acids can often be extensively oxidised, compromising their proposed 
113 biological function (11, 12). 
114 The Scientific Advisory Committee on Nutrition (SACN) recommends a long chain Ω-3PUFA intake 
115 of 450 mg/day. In comparison, UK intakes of EPA and DHA are estimated at 244 mg/day (131 
116 mg/day from oil-rich fish) (13), with potentially lower intakes in ethnic minority groups. Hence, there 
117 is ample scope to explore strategies to increase Ω-3PUFA intakes in the UK diet, potentially through 
118 enrichment strategies targeting foods such as dairy and meat (especially poultry) (13), with a view to 
119 improving cardio-metabolic health. While Ω-3PUFA intake is low in the Western population, Ω-
120 6PUFA consumption remains comparatively high, through regular intake of seed oils and food 
121 products. It is understood that the ratio of Ω-6:Ω-3PUFA has recently shifted from a balanced 1:1 to 
122 ~20:1, with implications for metabolism, specifically the production of pro-inflammatory molecules, 
123 such as prostaglandins and leukotrienes (14).
124
125 Importance of Skeletal Muscle Tissue for Cardiometabolic Health and Physical 
126 Function 
127 The term cardio-metabolic risk describes a family of risk factors of metabolic origin that increase the 
128 risk of developing CVD such as coronary heart disease, stroke, type 2 diabetes mellitus (T2DM) and 
129 chronic kidney disease. Skeletal muscle tissue plays a crucial, albeit often underappreciated, role in 
130 maintaining cardio-metabolic health and offsetting morbidities commonly associated with advancing 
131 age (15). Accounting for ~40% of total body mass (16), skeletal muscle is described as a plastic tissue 
132 that is capable of (mal)adaptation to physical (in)activity and diet. As the primary site of blood 
133 glucose disposal, skeletal muscle accounts for ~30% of postprandial glucose uptake (17). Low muscle 
134 mass is associated with a reduced resting metabolic rate that can lead to the accumulation of fat mass 
135 (15). Therefore, the maintenance of skeletal muscle mass over the lifecourse is critical in regulating 
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5136 blood glucose homeostasis and reducing the risk of T2DM, as well as other associated cardio-
137 metabolic diseases. In addition, skeletal muscle serves as the body’s primary storage site for amino 
138 acids and, during starvation or in the context of conditions such as acquired immune deficiency 
139 disorder (AIDS) by providing gluconeogenic precursors that are crucial for survival (18). Beyond 
140 metabolic health, it is widely recognised that skeletal muscle is crucial in preserving physical 
141 function, mobility and ultimately independence during older age. 
142 An inevitable, albeit partially modifiable, feature of the ageing process concerns the progressive 
143 decline in skeletal muscle mass, strength and function. Muscle atrophy begins as early as the fourth 
144 decade of life (19), continues at a rate of ~1% of total muscle mass per year until 70 years (20), and 
145 increases to ~1.5% of total muscle mass per year above 80 years old (21). Alarmingly, the decline in 
146 muscle strength with advancing age typically exceeds the decline in muscle mass, with annual 
147 declines of 3-4% in strength commonly reported (22). Once the decline in muscle strength and muscle 
148 mass fall below critical thresholds, older adults are classified as sarcopenic (23). This condition is 
149 associated with a 2-3 fold increase in risk of falling, bone fractures, loss of independence and 
150 increased mortality (24, 25). According to a recent report, additional health and social care costs 
151 associated with sarcopenia in the UK are currently estimated to be £2.5 billion per year (26).  
152 In 2016, sarcopenia was recognised as an independent geriatric condition, with its own International 
153 Classification of Disease code. Compounding this progressive loss of functional ability, the age-
154 related decline in muscle mass and strength is associated with an increased cardio-metabolic health 
155 risk. In this regard, a recent study demonstrated that low muscle strength was associated with 
156 increased risk of all-cause mortality from cardiovascular disease (CVD), cancer and respiratory 
157 disease (27). Similarly, low muscle strength has been associated with higher incidence of T2DM (27), 
158 with findings more equivocal for low muscle mass (28, 29). Conversely, the increased risk of CVD 
159 mortality observed in patients with T2DM is attenuated in those individuals with greater grip strength 
160 (30). Taken together, these observational data provide compelling evidence that the maintenance of 
161 muscle mass and strength with advancing age is critical for the management of cardio-metabolic 
162 health risk. 
163 The decline in muscle mass with advancing age often occurs in concert with an increase in fat mass. 
164 This age-related phenomenon is referred to as sarcopenic obesity. It is well established that obesity 
165 independently increases the risk of many cardio-metabolic health outcomes such as myocardial 
166 infarction, stroke, some cancers and all-cause mortality (31-33). Evidence also suggests that when 
167 sarcopenia and obesity are combined, the debilitating effects are additive. For example, whilst 
168 sarcopenia and obesity are independently associated with increased risk of all-cause mortality 
169
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 CI 1.03-1.42) (sarcopenia hazard ratio (HR) 1.41 (95% 1.22-1.63) and obesity HR 1.21 (95%CI 
6170 compared to lean non-sarcopenic individuals, all-cause mortality risk is even greater (HR 1.72 (95% 
171 CI 1.35-2.18)) in sarcopenic obese men (34). Therefore, it seems prudent to target the 
172 maintenance/increase of muscle mass, strength and function alongside the loss of fat mass to optimal 
173 levels in older adult populations. Before establishing targeted interventions to offset the age-related 
174 decline in muscle mass and increase in fat mass, it is important to understand the causal mechanism(s) 
175 that underpin the decline in muscle mass with advanced age. 
176
177 Causal Mechanisms that Underpin the Decline in Muscle Mass, Strength and 
178 Function with Age
179 Although sarcopenia affects ~10-30% of community-dwelling men and women aged 60+ worldwide, 
180 the underlying pathology of this clinical condition is not fully understood. Clearly, the underlying 
181 cause of sarcopenia is multifactorial, with interconnected and complex contributing factors. In terms 
182 of muscle atrophy, contributing factors include, but are not limited to, chronic low-grade 
183 inflammation, elevated levels of oxidative stress, DNA damage, mitochondrial dysfunction and 
184 hormonal changes (35). Ultimately however, from a metabolic standpoint, the decline in muscle mass 
185 with advanced age is underpinned by a state of negative muscle protein balance. 
186 Two possible metabolic drivers of negative muscle protein balance exist. First, an impaired 
187 stimulation of muscle protein synthesis (MPS), defined as the rate by which freely available amino 
188 acids in the blood or muscle amino acid pools are incorporated into functional muscle protein. 
189 Second, an upregulation of muscle protein breakdown (MPB), defined as the rate by which muscle 
190 protein is degraded into amino acid precursors. There is general consensus that basal, post-absorptive 
191 rates of MPS are comparable between young and older adults (36-38). In contrast, several studies have 
192 reported suppressed postprandial rates of MPS in response to amino acid feeding in older adults 
193 compared with their younger counterparts (39). The concept of this so-called ‘anabolic resistance’ has 
194 been conceived from this observation and describes the age-related impairment in response of MPS 
195 to ingesting a meal-like (~20 g) quantity of protein and/or other typically robust anabolic stimuli such 
196 as mechanical loading, i.e., structured exercise training. At the molecular level, this age-related 
197 impairment in MPS appears to be mediated by a dysregulation in the Akt-mTOR (mechanistic target 
198 of rapamycin) cell signalling cascade that controls the rate limiting translation initiation step of MPS 
199 (40). As such, anabolic resistance is widely regarded as one of the key drivers of sarcopenia. Moreover, 
200 as further evidence of the interplay between mechanisms underlying sarcopenia, animal studies have 
201 demonstrated that low grade inflammation, which is particularly prevalent in sarcopenic obese 
202 individuals, impairs the stimulation of MPS in response to food intake (41). Hence, there is a clear 
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7203 biological rationale to establish non-pharmacological lifestyle-friendly interventions that target 
204 overcoming both anabolic resistance and low grade inflammation in older adults. 
205 In practical terms, the progressive decline in muscle mass and strength is exacerbated by periods of 
206
207 term periods of limb immobilisation caused by injury (i.e. accidental falls) to longer-term periods of 
208 bed-rest inflicted by illness and/or cardio-metabolic disease. A reduction in physical activity, as 
209 typically quantified by step count, provides another important, albeit less extreme, example of muscle 
210 disuse. Accordingly, age-related anabolic resistance is exacerbated by reducing physical activity 
211 levels (44), limb immobilisation (42, 45) and bedrest (46). Moreover, recent evidence suggests that age-
212 related anabolic resistance is further exacerbated in overweight and/or obese older adults (47) (Figure 
213 2) and in response to a period of high-fat feeding (48). Thus, it follows that optimising diet and lifestyle
214 strategies for maintaining muscle health is of critical importance in sarcopenic older adults. In this 
215 regard, given the potent anti-inflammatory properties of Ω-3PUFA (49) and recent evidence that Ω-
216 3PUFA exhibit anabolic properties (50, 51), the role of dietary Ω-3PUFA intake in combating 
217 sarcopenia has received considerable recent attention. 
218 <<< Insert figure 2 here (47, 52-55) >>>
219 Diverse Biological Roles of Long Chain Omega-3 Fatty Acids 
220 A key determinant of physiological function at the cellular level includes the fatty acid composition 
221 of the phospholipid cell membrane. Membrane fatty acid composition is modulated by metabolic, 
222 genetic and hormonal factors, and of particular relevance to this review, dietary intake of fatty acids. 
223 As detailed in Dietary Sources of Very Long Chain Omega-3 Fatty Acids, the western diet is generally 
224 rich in Ω-6PUFA (e.g. linoleic acid) relative to Ω-3PUFA. This pattern is reflected in the constituent 
225 fatty acid composition of cell membranes which typically range from 10-20% for Ω-6PUFA and 2-
226
227 manner by dietary intake of Ω-3PUFA (57). Functionally, the most important Ω-3PUFA are EPA and 
228 DHA and many research studies have investigated the physiological properties of EPA/DHA, 
229 primarily due to their potential to reduce inflammation (56). 
230 Whilst inflammation is an important defence mechanism of the immune system to protect humans 
231 from infection, unresolved pathological inflammation can result in damage and disease. For example, 
232 and as detailed previously, low grade chronic inflammation has been implicated in the aetiology of 
233 sarcopenia but also many cardiometabolic conditions. There is a host of research demonstrating that 
234 increasing Ω-3PUFA intake serves to reduce inflammation, as reviewed previously (56). As 
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muscle disuse (42, 43). Examples of skeletal muscle disuse range in duration and severity from short-
5% Ω-3PUFA (56). The membrane composition of Ω-3PUFA can be elevated in a dose-dependent 
8235 inflammation has been associated with many cardio-metabolic conditions, it has been suggested that 
236 Ω-3PUFA supplementation may be of therapeutic use. For example, early observational studies in 
237 Inuits demonstrated that even though this population consumed very high fat diets, the prevalence of 
238 heart disease was low, with this inverse relationship attributed to the high dietary Ω-3PUFA intake 
239 (58, 59). In contrast, a recent meta-analysis demonstrated that increasing EPA and DHA consumption 
240 has minimal, or no effect, on mortality or cardiovascular health (60), with the authors calling for a halt 
241 in further studies until ongoing large trials are fully reported.  
242 In addition to their anti-inflammatory properties and role in regulating immune function, Ω-3PUFA 
243 exhibit other physiological roles due to their incorporation into all cell types. Therefore, it is not 
244 surprising that the physiological roles of EPA and DHA are not limited to the immune system. For 
245 example, DHA is vital for fetal brain and retinal development given the high propensity for DHA 
246 incorporation in brain and retinal membrane phospholipids that are crucial for the functional 
247 development of these tissues (61). Since the recent observation that EPA and DHA supplementation 
248 results in an increased incorporation of EPA and DHA in muscle cells (51), there has been a growing 
249 interest in the physiological effects of such a change for muscle health with advancing age. 
250 Role of Long Chain Omega 3 Fatty Acids in Prevention and Treatment of Sarcopenia 
251
252 Dietary Ω-3PUFA have received considerable recent attention in the context of optimising diet for 
253 the management of sarcopenia. Extending early epidemiological data, which found that fatty fish 
254 consumption was positively associated, in a dose-response manner, with grip strength (62), two 
255 seminal experimental studies in healthy young, middle-aged and older adults sparked interest in the 
256 potential muscle anabolic action of Ω-3PUFA (63, 64). These proof-of-principle, acute metabolic, 
257 studies were conducted under controlled laboratory conditions and measured rates of MPS under 
258 basal (fasted and rested) and simulated fed conditions before and after 8 weeks of fish oil (4 g/day) 
259 derived Ω-3 PUFA supplementation (1.86 g EPA, 1.50 g DHA per day). Amino acids and insulin 
260 were infused intravenously to partially mimic the ingestion of a protein-rich mixed macronutrient 
261 meal. Whereas the basal response of MPS was not modulated by Ω-3PUFA, the feeding-induced 
262 increase in MPS was potentiated by 30-60% after 8 weeks of fish oil supplementation compared with 
263 before supplementation (63, 64). 
264 Perhaps surprisingly, at least from a mechanistic standpoint, in these studies (63, 64) no changes in 
265
266 of inflammation were observed over the 8 week period of fish oil supplementation. However, the 
267 phosphorylation status of intramuscular cell signalling proteins known to upregulate MPS (e.g. 
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tumero necrosis factor alpha (TNF-ɑ) or C-reactive protein (CRP) concentrations as systemic markers 
9268 mTORC1-p70S6k1) was potentiated in response to simulated feeding following dietary fish oil 
269 supplementation. Consistent with this observation, our laboratory reported an increase in the 
270 proportion of Ω-3PUFA, specifically EPA — to increase in the muscle cell following 4 weeks of fish 
271 oil (5 g/day) derived Ω-3PUFA in healthy young men (51). Such structural modifications to the muscle 
272 cell membrane also were associated with an increased phosphorylation of mTORC1 — a nutrient-
273 sensitive intramuscular cell signalling protein, and focal adhesion kinase — a mechanically sensitive 
274 kinase known to regulate MPS. Therefore, the primary causal mechanism that appears to underpin 
275 the anabolic action of Ω-3PUFA relates to modifying the lipid profile of the muscle phospholipid 
276 membrane and subsequently upregulating the activity of intracellular signaling proteins, rather than 
277 an anti-inflammatory response. 
278 In recent years, we (65, 66) and others (67) have extended these acute metabolic studies to investigate the 
279 anabolic and/or anti-catabolic potential of Ω-3PUFA in young and older adults using more 
280 physiologically relevant experimental study designs (Figure 3). Rather than the intravenous infusion 
281 of amino acids and insulin to simulate feeding, anabolic stimuli included either an orally ingested 
282 dose of intact protein, a standardised mixed macronutrient meal and/or a resistance exercise session(s) 
283 administered over a period of 1-4 days. Informed by our in vitro experiment with fully differentiated 
284 C2C12 cells whereby EPA, rather than DHA, was shown to both upregulate the MPS response to a 
285 leucine stimulus and downregulate MPB (68), these studies have primarily administered high dose (3-
286 5g/day) fish oil supplements that are rich in EPA content. Accordingly, Lalia et al. (67) reported that 
287 fish oil supplementation (3.9 g/day) augmented the acute response of MPS to conducting a single 
288 bout of resistance exercise alongside feeding a protein-containing meal by ~30% in older adults. As 
289 a note of caution, data values for MPS (expressed as fractional synthesis rate) were remarkably high 
290 in this study, calling into question the validity of these findings. 
291 However, study findings regarding the influence of Ω-3PUFA supplementation on postprandial rates 
292 of MPS have been equivocal, which may be attributed to differences in study design (i.e., the duration 
293 and dose of Ω-3PUFA supplementation, choice of control supplement and technique used to measure 
294 MPS) and/or participant characteristics. For instance, we observed no differences in p70S6K1 kinase 
295 activity or free-living integrated rates of MPS measured over 4 days (assessed by recently re-
296 introduced and less invasive orally administered deuterium oxide tracer methodology) between two 
297 groups of older adults that combined resistance training with either fish oil (3 g/day) or safflower oil 
298 (3 g/day) supplementation (65). In addition, we demonstrated that 8 weeks of fish oil (5 g/day) derived 
299 Ω-3PUFA (3.5 g/day EPA) supplementation failed to modulate the 4 hour (as measured by the 
300 precursor-product method with intravenous infusion of labelled phenylalanine) MPS response to 
301 ingestion of a 30g whey protein bolus under both rested and post-exercise conditions in trained young 
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302 men (66). Follow-up studies designed with a mechanistic focus are warranted to further explore these 
303 findings. We cannot discount the possibility that ingesting 30g of whey protein saturated the muscle 
304 protein synthetic machinery in our cohort of “nutrient-sensitive” trained young men (52), and although 
305 more relevant to simulating daily lifestyle patterns, free-living measurements of MPS integrating 
306 postabsorptive and postprandial physiological states might have “diluted” the chance of detecting any 
307 subtle, but physiological relevant, anabolic action of Ω-3PUFA (65). Taken together, based on 
308 currently available evidence, these data indicate the anabolic action of Ω-3PUFA may confer greater 
309 application to older adults who exhibit a state of anabolic resistance (Figure 3). 
310 <<< Insert figure 3 here (47, 63, 64, 66, 67) >>>
311
312 longitudinal studies that obtained clinically-relevant endpoint measurements of muscle mass, strength 
313 and function, particularly when older women were studied. Expanding upon their initial work, Smith 
314 and colleagues (4) have demonstrated that daily ingestion of Ω-3PUFA (1.86g EPA and 1.50g DHA) 
315 over 6 months increased thigh volume by ~3.5% and handgrip strength by ~6% in older adults, despite 
316
317
319 muscle strength and quality (calculated as peak torque relative to muscle anatomical cross sectional 
320 area), but not muscle mass, following 18 weeks of structured bi-weekly resistance exercise training 
321 were augmented with dietary fish oil-derived Ω-3PUFA supplementation in older women (65). 
322 However, no such benefit of Ω-3PUFA ingestion was observed when older men were studied. 
323 Consistent with this observation, an earlier study supplemented older women with 2g/day of fish oil 
324 during 90 days of resistance training and reported greater strength gains compared with training alone 
325 (5). However, we contend that these data from Rodacki and coworkers (5) should be treated with 
326 caution since no placebo group was included in the study design, the changes in blood Ω-3PUFA 
327 composition were minimal, and no direct measures of muscle mass or MPS were collected. It follows 
328 that further studies are warranted to, first confirm this apparent sex-difference in the muscle adaptive 
329 response to resistance training with Ω-3PUFA ingestion and, second, determine the mechanism(s) 
330 that underpins this apparent sexual dimorphism in response to ingested Ω-3PUFA. 
331 Accumulating evidence also substantiates a “protective” role for Ω-3PUFA ingestion during short-
332 term periods of muscle disuse. In this regard, an elegant recent study by McGlory and colleagues (71) 
333 investigated the influence of Ω-3PUFA supplementation on changes in muscle mass and integrated 
334 rates of MPS following 2 weeks of limb immobilisation in young women. The decline in muscle 
335 volume elicited by short-term limb immobilisation was attenuated by ~6% with Ω-3PUFA 
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The anabolic action of Ω-3PUFA in ageing muscle has been partially supported by a series of 
318 (70) are known predictors of all-cause mortality. Moreover, we demonstrated that improvements in 
particularly significant given that, as mentioned previously, handgrip strength (69) and general strength 
the absence of structured exercise training. The clinical implications of these remarkable data are 
11
336 supplementation (a decrease of 8%) vs. the sunflower oil control (a decrease of 14%). Moreover, 
337 following 2 weeks of rehabilitation whereby study participants resumed their habitual physical 
338 activity levels, muscle volume returned to baseline levels with Ω-3PUFA supplementation, but 
339 remained below baseline in the control group. Accompanying the retention of muscle volume during 
340 simulated muscle disuse atrophy was a higher integrated response of MPS both at immediate 
341 cessation of limb immobilisation and following two weeks of remobilisation. Interestingly, Ω-3PUFA 
342 supplementation had no protective effect on the decline in muscle strength. Consistent with this 
343 observation, albeit using an animal model, rats fed a Ω-3PUFA-rich diet during hindlimb suspension 
344 (simulating leg immobilisation) demonstrated an attenuated loss of muscle mass vs. rats fed a corn 
345 oil-rich diet (72). Taken together, based on multiple lines of evidence, the preponderance of available 
346 data suggests that the optimal diet for maintaining muscle mass with age should consider the dietary 
347 intake of Ω-3PUFA. Future studies are warranted to investigate the impact of Ω-3PUFA ingestion on 
348 age-related changes in body composition in sarcopenic, obese, population groups.  
349 Conclusions 
350 Skeletal muscle plays an underappreciated role in cardio-metabolic health and disease. The age-
351 related decline in muscle mass and muscle strength is explained, in part, by anabolic resistance. 
352 Convincing evidence exists that dietary Ω-3PUFA ingestion acutely increases the anabolic sensitivity 
353 of skeletal muscle in older adults with long-term data indicating a beneficial effect of Ω-3PUFA 
354 ingestion on muscle mass and/or function, particularly in women. Promising, albeit preliminary, 
355 evidence suggests that dietary Ω-3PUFA ingestion may form part of an effective non-
356 pharmacological strategy to attenuate the decline in skeletal muscle mass associated with periods of 
357 muscle disuse, e.g. limb immobilisation. Moving forward, larger-scale experimental studies (73) 
358 should be repeated in more compromised populations (i.e., frail older adults, sarcopenic obese adults, 
359 etc.) to evaluate the application of Ω-3PUFA ingestion during more extreme periods of muscle disuse, 
360 i.e. bedrest during surgery and hospitalisation.
361
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589 Figure legends
590
591 Figure 1. Commonly consumed Ω-3PUFA rich food sources in the UK diet.  Data extracted from 
592 Composition of foods integrated dataset (CoFID) (74).
593 Ω-3PUFA, very long-chain omega-3 polyunsaturated fatty acids; ALA, alpha-linoleic acid; EPA, 
594 eicosapentaenoic acid; DHA, docosahexaenoic acid.
595
596 Figure 2. Theoretical model of muscle “anabolic resistance” associated with ageing and obesity. 
597
598
599
600
601 of pork containing 36 g of protein. 
602 Small protein feed, 10g of protein; moderate protein feed, 20g of protein, large protein feed, 36-40g 
603 of protein. MPS, muscle protein synthesis; Yg, young adults. Old, Older adults. 
604
605 Figure 3: Overview of findings from experimental studies that investigated the influence of fish oil-
606 derived Ω-3PUFA supplementation on the response of muscle protein synthesis (MPS) to amino acid 
607 provision in young and older adults. 
608
609 years) adults consumed fish oil (4 g/day; 1.86 g/day EPA and 1.50 g/day DHA) capsules over 8 weeks 
610 and MPS was measured pre and post supplementation in response to the intravenous infusion of 
611
612 and 1.50 g/day DHA) or corn oil capsules over 8 weeks and MPS was measured in response to the 
613
614 g/day; 3.5 g/day EPA and 0.9 g/day DHA) or coconut oil capsules over 8 weeks and MPS was 
615
616 Older (65-85 years) adults consumed fish oil (3.9 g/day) capsules over 16 weeks and MPS was 
617
618 ingesting 15g of milk protein isolate in older (66-73 years) obese (BMI >30) adults. 
619 FSR, fractional synthesis rate; Yg, young adults, Old, older adults; AA, amino acid, WP, whey 
620 protein; REx, resistance exercise.
621
622
623
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Data are generated from citations denoted by number in parentheses: (52) Young (18-35 years) adults 
ingested 10, 20 or 40g of whey protein; (53) Older (65-75 years) ingested 10g of whey protein; (55)
Older (65-75 years) ingested 20 or 40g of soy protein; (47) Older (66-73 years) obese (BMI >30) adults 
ingested 15g of milk protein isolate; (54)  Young (23-30 years) obese (BMI >33) adults ingested 170g 
Data generated from citations denoted by number in parentheses: (64) Young and middle-aged (~39 
amino acids and insulin. (63) Older (≥ 65 years) adults consumed fish oil (4 g/day; 1.86 g/day EPA 
intravenous infusion of amino acids and insulin. (66) Young (~ 21 years) adults consumed fish oil (5 
measured in response to ingesting 30g of whey protein at rest and following resistance exercise. (67)
measured in response to an acute bout of resistance exercise. (47) MPS was measured in response to 
Figure 1 
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